The Apa-RP study from Neal Shore, MD, FACS, and colleagues sought to determine the effects of apalutamide plus androgen deprivation therapy (ADT) on the biochemical recurrence (BCR)-free rate in patients with high-risk localized prostate cancer who underwent radical prostatectomy (RP). The study was published in the Journal of Urology. ...
Localized Prostate Cancer
Advertisement
Latest News
Development of a novel risk score for early intensification approaches to RT or salvage RT for pN1 receiving RP.
Investigators found that the NCHT cohort demonstrated increased 3-year bPFS benefits compared to the NHT cohort.
Dr. Spratt ponders the evolving integration of RT with systemic treatments, challenges in counseling patients, and more.
Prostate-specific antigen density was the only clinical variable significantly associated with csPCa other than PI-RADS 5.
Dr. Canfield shares real-world active surveillance among men with localized PC tested with the genomic prostate score assay.
The 17-gene GPS assay can help physicians with clinical management plans for patients with localized PC.
Advertisement
Prostate Cancer Knowledge Hubs
Curated clinical content based on prostate cancer types, therapies, and technologies
Conference Coverage
Dr. Li highlights the significance of adverse pathologic features at radical prostatectomy for AS-eligible patients.
Continuing his discussion at the AUA 2024 Annual Meeting, Dr. Narayan highlights the latest news on nadofaragene firadenovec.
Dr. Narayan breaks down the 5-year follow-up data on nadofaragene firadenovec for patients with BCG-unresponsive NMIBC.
Development of a novel risk score for early intensification approaches to RT or salvage RT for pN1 receiving RP.
Drs. Joyce and Psutka consider patient counseling for adjuvant RCC therapy, and biomarkers and imaging before treatment.
Drs. Ambinder and Sonpavde provide an update for CheckMate 901, characterizing treatment benefit in responders.
Advertisement
Advertisement
Trending
Data on the type of treatment received in each line of therapy, as well as the attrition rates, were recorded.
In patients with RCC, around 20% demonstrate non-clear cell histology, including various histology types.
Dr. Li highlights the significance of adverse pathologic features at radical prostatectomy for AS-eligible patients.
